Clene Inc. 8-K

What Happened

• On May 4, 2026 Clene Inc. (CLNN) announced that, following a Type C in-person meeting and receipt of final meeting minutes from the FDA, it plans to file a New Drug Application (NDA) under the Subpart H accelerated approval pathway (21 CFR 314.510) for CNM-Au8 in amyotrophic lateral sclerosis (ALS). The company intends to submit the NDA in the third quarter of 2026. The FDA stated Clene’s proposed data “may be capable of supporting” an accelerated-approval NDA and indicated neurofilament light (NfL) could potentially serve as a “reasonably likely surrogate endpoint.”

Key Details

• Planned NDA submission timing: third quarter of 2026.
• Regulatory pathway: Subpart H accelerated approval (21 CFR 314.510).
• FDA view: Proposed data may support accelerated approval; NfL may be a reasonably likely surrogate endpoint, but the FDA requested additional information linking the magnitude of NfL reduction to clinical benefit.
• Supporting data sources: Phase 2 HEALEY ALS Platform Trial and open‑label extension, Phase 2 RESCUE‑ALS Trial, and NIH Expanded Access Protocol; Phase 3 confirmatory study planned to commence in Q1 2027. CNM‑Au8 has FDA Orphan Drug Designation for ALS.

Why It Matters

• For investors, this filing plan is a major regulatory milestone: an NDA submission under accelerated approval could shorten the time to potential approval if the FDA accepts NfL as a surrogate endpoint and the data meet requirements. However, the FDA has asked for additional analyses tying biomarker changes to clinical benefit, and the planned Phase 3 confirmatory trial (expected Q1 2027) will still be required to verify clinical efficacy. The timing and outcome remain subject to FDA review and other development and regulatory risks noted in the company’s forward‑looking statements.